Drug Search Results
More Filters [+]

Dazukibart

Alternative Names: Dazukibart, pf-06823859, pf06823859, pf 06823859
Latest Update: 2024-10-23
Latest Update Note: Clinical Trial Update

Product Description

interferon, beta 1, fibroblast (IFNB1) Blocker

Mechanisms of Action: IFNB Agonist

Novel Mechanism: No

Modality: Antibody

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Pfizer
Company Location: NEW YORK NY 10017
Company CEO: Albert Bourla
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Dazukibart

Countries in Clinic: Argentina, Belgium, Bulgaria, Canada, China, France, Germany, Greece, Hungary, India, Israel, Italy, Japan, Korea, Mexico, Poland, Slovakia, South Korea, Spain, Sweden, Taiwan, United States, Unknown Location

Active Clinical Trial Count: 13

Highest Development Phases

Phase 3: Dermatomyositis|Myositis|Polymyositis

Phase 2: Lupus Erythematosus, Cutaneous|Lupus Erythematosus, Systemic

Phase 1: Healthy Volunteers

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

C0251013

P2

Unknown Status

Lupus Erythematosus, Cutaneous|Lupus Erythematosus, Systemic

2026-11-17

C0251006

P3

Recruiting

Dermatomyositis|Polymyositis

2026-07-23

C0251013

P2

Recruiting

Lupus Erythematosus, Cutaneous|Lupus Erythematosus, Systemic

2025-12-17

jRCT2031230382

P3

Recruiting

Myositis

2025-12-04

Recent News Events